Global Geographic Atrophy Market Reaches $X Billion by 2032

The Geographic Atrophy (GA) Market, valued at USD 23.7 billion in 2023, is projected to reach USD 50.0 billion by 2032, growing at a compound annual growth rate (CAGR) of 8.6% over the forecast period from 2024 to 2032. The market's expansion is driven by the increasing prevalence of age-related macular degeneration (AMD), a key cause of geographic atrophy, and significant advancements in both diagnostic and therapeutic approaches for treating this debilitating condition.

Geographic atrophy, characterized by the progressive degeneration of the retina, leading to permanent vision loss, is one of the leading causes of blindness in older adults. The growing aging population and increased awareness about the condition have fueled demand for treatments, contributing to the market's projected growth.

Get A Free Sample Report on Geographic Atrophy Market @ snsinsider.com/sample-request/2480

Market Overview

Geographic atrophy (GA) is a severe form of age-related macular degeneration (AMD), and it causes the deterioration of retinal cells in the macula, which is responsible for sharp, central vision. As the condition progresses, individuals with GA experience gradual loss of vision, often leading to complete blindness. There is currently no cure for GA, but recent advancements in drug development, as well as a deeper understanding of the disease's mechanisms, are accelerating the availability of treatment options.

The Geographic Atrophy Market includes both pharmaceutical treatments and diagnostic tools aimed at managing the condition. With a growing number of therapies in the pipeline, particularly gene therapies, biologics, and anti-inflammatory treatments, the market is poised for significant growth in the coming years.

Key Market Drivers

1. Rising Prevalence of Age-Related Macular Degeneration (AMD)
   The increasing prevalence of AMD, a leading cause of geographic atrophy, particularly among the aging global population, is one of the primary drivers of the GA market. As the global population ages, the incidence of AMD and related conditions, including GA, is expected to rise significantly, creating a substantial demand for effective treatment options.

2. Advancements in Treatment Modalities
   There has been significant progress in the development of therapies targeting geographic atrophy. Gene therapies, stem cell treatments, and innovative biologics are showing promise in slowing down or halting disease progression. These therapeutic advancements have brought new hope to patients and are expected to contribute to the market's expansion.

3. Growing Awareness and Early Detection
   As awareness of geographic atrophy increases, more individuals are seeking early diagnosis and treatment, which is expected to drive demand for diagnostic tools and therapies. Early intervention is crucial in slowing disease progression and preventing severe vision loss.

4. Investments in Research and Development
   With substantial investments in R&D by leading pharmaceutical companies and research institutions, the geographic atrophy market is witnessing the introduction of novel therapies. These investments are expected to accelerate the development of more effective and personalized treatments for the condition.

5. Improved Access to Healthcare
   Increased access to healthcare services, especially in developing regions, has led to more individuals being diagnosed with geographic atrophy. The rise in healthcare access, along with advancements in imaging and diagnostic tools, is driving the need for more effective solutions for GA.

Make an inquiry on the Geographic Atrophy Market Report @ snsinsider.com/enquiry/2480

Key Market Segments

• By Age Group

  • Above 60 Years

  • Above 75 Years

By Diagnosis

• Fundus Autofluorescence (FAF)

• Optical Coherence Tomography Angiography (OCT-A)

• Multifocal Electroretinography (mfERG)

By Therapeutic Agents

• Late-stage (Phase III)

• Phase II

• Phase I

• Pre-clinical stage & Discovery candidates

Key Players

• Iveric Bio (Zimura (avacincaptad pegol))

• Alkeus Pharmaceuticals, Inc. (ALK-001)

• Apellis Pharmaceuticals, Inc. (APL-2)

• Genentech, Inc. (OpRegen)

• Stealth BioTherapeutics (Elamipretide)

• Allegro Ophthalmics, LLC (Risuteganib)

• Gyroscope Therapeutics Limited (GT005)

• Regenerative Patch Technologies, LLC (CPCB-RPE1)

• NGM Biopharmaceuticals Inc. (NGM621)

• Novartis (PPY988)

• Perceive Biotherapeutics, Inc. (VOY-101)

• Annexon, Inc. (ANX007)

• Aviceda Therapeutics (AVD-104)

• Ionis Pharmaceuticals, Inc. (IONIS-FB-LRx)

• Astellas Pharma Inc. (ASP7317), and others.

Conclusion

The Geographic Atrophy (GA) Market is set for substantial growth, driven by an aging population, advances in genetic testing and imaging technologies, and the ongoing development of novel therapeutics. With several promising treatments in the pipeline and increasing awareness of the disease, the market is expected to expand rapidly. As the demand for effective management options for geographic atrophy grows, the opportunities for both established and emerging players in the market are significant.

Buy a Single-User PDF of Geographic Atrophy Market @ snsinsider.com/checkout/2480

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us:
Akash Anand – Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)